Modus Therapeutics Holding AB (MODTX) AI Stock Analysis

• Market Cap: €55.95M
• Dividend Yield: N/A
• Average Volume (3M): 561.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.95
• Revenue Growth: N/A
• EPS Growth: 21.80%
• Country: SE
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 121,628,494
• 10 Day Avg. Volume: 1,097,890
• 30 Day Avg. Volume: 561,489
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: ―

Modus Therapeutics faces significant financial challenges typical of early-stage biotech companies, with no revenue and substantial reliance on external funding. Technical analysis shows some positive momentum, but valuation indicators highlight the high risk associated with its current financial state. The stock score reflects the significant financial risks, tempered by moderate technical momentum.

Modus Therapeutics Holding AB Business Overview & Revenue Model

Company Description

Modus Therapeutics Holding AB (MODTX) is a Swedish-based biotechnology company focused on the development of innovative therapies for patients with significant unmet medical needs. The company primarily operates in the healthcare and pharmaceutical sectors, with a core emphasis on developing drug candidates targeting rare diseases and conditions that lack effective treatment options.

How the Company Makes Money

Modus Therapeutics generates revenue through the development and commercialization of its drug candidates. The company's primary revenue streams include licensing agreements, where it partners with larger pharmaceutical companies to co-develop and market its therapies, and milestone payments received as drug candidates progress through clinical trials and regulatory approvals. Additionally, Modus may earn royalties on sales of successfully commercialized products. The company also engages in research collaborations and may receive grants or funding from governmental or non-profit organizations to support its research and development activities.

Modus Therapeutics Holding AB Financial Statement Overview

Summary

Modus Therapeutics exhibits typical characteristics of an early-stage biotech firm with no revenue generation and significant operational expenses. The company maintains liquidity through equity financing, but the absence of revenue and profitability poses substantial risks.

Income Statement

Modus Therapeutics has consistently reported zero revenue, which is common in early-stage biotech firms focusing on R&D. However, the absence of revenue combined with significant net losses indicates financial strain. Negative EBIT and EBITDA margins further highlight the lack of operational profitability.

Balance Sheet

The company's balance sheet shows a reliance on equity financing, as evidenced by the zero debt in recent years. However, the low stockholders' equity and negative equity in prior years indicate financial instability. The company has been able to maintain a positive cash position, but the equity ratio is low, suggesting vulnerability to financial shocks.

Cash Flow

Operating cash flow remains negative, which is typical for a biotech company in the development phase. The significant cash burn, offset by financing activities, indicates a need for continuous funding. The free cash flow is consistently negative, reflecting the high operational and R&D expenditures without income generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-15.35M	-15.84M	2.00K	-18.01M	-20.69M	-6.02M
Net Income	-15.26M	-15.54M	-17.90M	-18.32M	-20.69M	-6.02M
Balance Sheet
Total Assets	6.17M	4.88M	20.04M	11.27M	21.19M	7.49M
Cash, Cash Equivalents and Short-Term Investments	5.32M	4.38M	19.06M	10.42M	20.65M	7.34M
Total Debt	5.00M	0.00	0.00	11.50M	0.00	26.00K
Total Liabilities	6.84M	2.75M	2.36M	13.86M	5.46M	496.00K
Stockholders Equity	-678.00K	2.14M	17.68M	-2.58M	15.73M	7.00M
Cash Flow
Free Cash Flow	-11.02M	-14.68M	-16.68M	-21.72M	-16.08M	-7.23M
Operating Cash Flow	-11.02M	-14.68M	-16.68M	-21.72M	-16.08M	-7.23M
Investing Cash Flow	0.00	0.00	0.00	0.00	-50.00K	0.00
Financing Cash Flow	5.00K	0.00	25.32M	11.50M	29.43M	13.20M

Modus Therapeutics Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MODTX, the sentiment is Negative. The current price of 0.46 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.41, and below the 200-day MA of 0.76, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 32.36 is Neutral, neither overbought nor oversold. The STOCH value of 6.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MODTX.

Modus Therapeutics Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LARK	52 Neutral	44.75M	-1.00	0.00%	8.89%	-94.12%	-25.83%
MODTX	42 Neutral	€55.95M	―	-1117.29%	―	―	21.80%
EXPRS2	41 Neutral	47.42M	-0.87	-55.62%	―	-13.08%	32.78%
SPRINT	39 Underperform	59.30M	-1.91	0.00%	―	-30.49%	-242.26%
SPAGO	38 Underperform	73.12M	-2.36	0.00%	―	-16.01%	59.53%
STABL	34 Underperform	17.63M	-1.37	0.00%	―	0.00%	68.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%